Agendia's MammaPrint shows significant agreement with other multi-gene breast cancer prognosis tests
In a publication in the New England Journal of medicine, Agendia's MammaPrint® 70 gene breast cancer prognosis test and three other multi gene tests are shown to be superior over conventional assessment of risk of future metastatic disease. This reinforces the reliability of multi-gene tests for breast cancer prognosis prediction. The authors conclude that, even though the multi gene tests have only minimal overlap in the genes used, they show a remarkable agreement in assigning patients to the same risk category. This is probably due to the fact that the different genes used track a common set of biological characteristics of the individual cancer, leading to a similar assessment of the risk of developing metastatic disease.
Dr. Charles Perou, senior author of the New England Journal of Medicine states in the publication that it is clear that these profiles provided significant additional information beyond that provided by grade (i.e. histological assessment of tumor aggressiveness). In a commentary in the same issue of the New England Journal of Medicine, Dr. Joyce O'Shaughnessy comments that multi-gene tests will alter medical practice such that in the future 30- to 50% fewer patients with ER-positive breast cancer will receive adjuvant chemotherapy.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Quick and reliable 3-D imaging of curvilinear nanostructures
The spontaneous and sophisticated side of self-assembly
Heraeus Noblelight Acquires Specialty Light Sources Company in the UK
Ovulation filmed from start to finish for the first time - New findings for fertility research
New blood test detects wide range of cancers - Test proved able to detect and indicate site of dozens of types of cancer with high accuracy
Gardner Denver Medical acquires ILS and Zinsser Analytic
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
‘Smart’ contact lenses could someday enable wireless glaucoma detection - Intelligent contact lens for quantitative intraocular pressure monitoring
Spectro Scientific acquired by AMETEK
Hach Lange announces name change
Trust in AI but not blindly - Artificial intelligence is sometimes met with scepticism but it has earned our trust